Objectives. Vaccinations are an important measure to prevent infections in immunocompromised patients. The knowledge of vaccination coverage and reasons for non-vaccination in patients with SLE is scarce. The aim of this study was to assess coverage rates of selected vaccinations in a representative sample of SLE patients and to identify predictors for non-vaccination.
Introduction
Infections are important factors for morbidity and mortality in SLE. Even in the past decade, >30% of deaths in SLE patients have been attributable to infections [1, 2] . In particular, immunosuppressive therapies increase susceptibility for infections. Modern treatment regimens and new or upcoming biologicals raise an additional need for effective management to prevent infections. One method to avoid certain infections is the use of vaccinations. The German Society for Rheumatology (DGRh) released recommendations for the use of vaccination in adult patients with chronic inflammatory rheumatic diseases. These are based on the recommendations of the German Standing Committee on Vaccination [3, 4] and approve vaccination against Pneumococcus, influenza, Haemophilus influenza and Meningococcus in patients receiving immunosuppressive therapy in addition to standard vaccinations [5] . Similar recommendations have been formulated by the EULAR in 2011 [6] .
Despite these recommendations, vaccinations rates often do not come up to the targeted rate. For instance, the German Health Update 2012 study depicted an influenza vaccination rate in Germany of 42.9% for patients with chronic diseases [7] , which is in line with rates of other European countries, such as England (52%), France (46%), Norway (37%) and Portugal (31%) [8] .
Reasons for non-vaccination or vaccine hesitancy can be patient or health-care professional (HCP) associated. Frequent concerns are the immune triggering of disease flares or the development of vaccine-induced diseases. In the immunosuppressive state, the administration of live attenuated vaccines is not being recommended, whereas inactivated whole-cell or subunit vaccines are safe because they do not contain live components of the pathogen. Several studies were able to prove safety and efficacy for non-live vaccines without an increase in disease activity or new clinical manifestations [9, 10] , although anecdotal evidence for the occurrence of disease flares exists. Providing this information to patients who will probably not be aware of these facts can help to reduce vaccination hesitancy. Vaccine hesitancy can also be caused by the doctor's reluctance to take responsibility for vaccination recommendations or their implementation [11] .
In this study, our main objective was to assess the rates and predictors of selected vaccinations in a representative sample of German SLE patients to evaluate the implementation of national and international recommendations. Furthermore, with our second objective we aimed to identify reasons and predictors for non-vaccination to assist vaccine management in SLE patients.
Methods
The LuLa study is a longitudinal survey on a multitude of SLE-associated factors that has been conducted annually by means of a self-reported questionnaire since 2001 among patients nationwide [12] .
The infrastructure of the German LE self-help community (GSHC) is used for study organization and preparation of data acquisition; anonymized data collection and scientific evaluation are guaranteed by a tertiary centre, whereas medical care of the participant is predominantly provided by anonymous physicians all over Germany. This minimizes the possibility of an expectancy bias such as the Rosenthal effect, which is of importance in self-reported questionnaires. Participants were recruited on individual invitation by their caring rheumatologist or the GSHC itself. Inclusion criteria were a confirmed diagnosis of SLE and returning the completed paper questionnaire. Digitization of the questionnaire was performed using two-pass verification by two persons to reduce data entry errors. Owing to the study design, data are solely patient reported. In comparison with other cohort studies and in particular with reference data from the national database of the German Collaborative Arthritis Centers at the German Rheumatism Research Centre, it was previously shown that data provided by LuLa participants are trustworthy and comparable. Therefore, these data can be considered as representative of SLE patients in Germany [12] .
The questionnaire was sent to 629 persons by the GSHC, 613 of whom had participated in the previous years and 16 who had entered the study during the enquiry period (November 2012 until October 2013). The return rate of completed questionnaires was on a par with the observed return rate of the past study years (92%).
Besides demographic data, clinical parameters such as co-morbidities, lupus-specific medication, disease activity, damage and health-related quality of life are collected in the yearly questionnaires. In 2013 we additionally enquired about vaccinations as a main topic using a compilation of questions regarding coverage, monitoring, application and patients' reservations. Possession and usage of the standardized vaccine record card (International Certificate of Vaccination or Prophylaxis issued by the World Health Organization), the application of selected vaccinations (tetanus in the past 10 years, diphtheria in the past 10 years, pneumococcus in the past 5 years, meningococcus in the past 5 years and influenza in the past 1 and 5 years) and the role of the attending physicians [general practitioner (GP), rheumatologist, internal specialist and others] in the process of monitoring and application of vaccines was surveyed. Selected standardized statements expressing reservations against vaccinations were queried: fear of vaccine damage or side-effects; fear of lupus flare; previous bad experience with vaccinations; already experienced vaccine side-effects; vaccinations weaken the immune system; vaccinations do not protect; and others.
Furthermore, we enquired about the health locus of control and beliefs about medicines to explore basic conceptual characteristics of the participants that possibly influence their attitude towards vaccinations.
The Beliefs about Medicines Questionnaire (BMQ) [13] is a validated questionnaire to assess beliefs about medication prescribed for a particular illness and beliefs about medications in general. The German questionnaire (BMQ-D) was translated and validated by the Department of Clinical Psychology and Psychotherapy, Philipps-University of Marburg, Germany and demonstrated comparable psychometric properties to the original BMQ. The BMQ-D comprises the specific scales (necessity, concern and benefit), the general scales harm and overuse, and an additional sensitivity to medicines scale. The scales are presented by 28 items, which are rated on a five-point Likert scale (from strongly disagree to strongly agree). Scores obtained for the items are summed to give the individual scale score, where higher scores indicate stronger beliefs in the scale concept.
The German version of the Multidimensional Health Locus of Control Scale [14] was used to assess the different health locus of control (HLC) scales. It distinguishes between the internal HLC int , considering one's own behaviour responsible for health, and two external dimensions, HLC doc and HLC chance , considering health-care professionals and chance, respectively, to be responsible for personal health. The dimensions are each measured by three items that are rated on a five-point Likert scale (from strongly disagree to strongly agree). A high score indicates a stronger belief in the importance of the specific dimension.
Health-related quality of life was assessed using the Short Form 12 Health Survey (SF-12) [15] , offering a mental component summary and a physical component summary. The SF-12 is based on the Short Form 36 (SF-36) and provides comparable results. Additionally, the physical functioning index of the SF-36 (SF-36-pfi) was assessed [16] .
Disease activity was surveyed using the patient-reported Systemic Lupus Activity Questionnaire [17] , which is based on the SLAM. It consists of 24 items covering disease symptoms in the previous 3 months. The questionnaire was translated and validated in different languages. The German version proved to have a strong correlation with the SLAM and presented good to excellent internal consistency [18] .
Damage was assessed using the patient-reported Brief Index of Lupus Questionnaire (BILD) [19] , which is based on the SLICC/ACR Damage Index (SDI). It consists of 28 items enquiring about organ damage accumulated since the diagnosis of SLE. The questionnaire was translated and validated in different languages. The German version proved to have comparable validity to the original BILD and a strong correlation with physician-reported damage (SDI) [20] .
To determine fatigue, we used the Fatigue Severity Scale, which was recommended by the ad hoc committee on SLE response criteria. It measures the impact of fatigue on nine specific types of functioning in the preceding 2 weeks. The average represents overall fatigue. Higher scores indicate greater levels of fatigue, and a score of <4 is considered normal [21] .
Statistical analysis
Data were analysed with the statistical software program IBM SPSS Statistics 23 (IBM Corp., Armonk, NY, USA). Proportions, mean, median, S.D., minimum and maximum were calculated where appropriate. Univariable analyses were carried out to depict significant differences using non-parametric rank tests because of the mostly skewed distributions of the variables. Two-tailed P-values for differences were calculated using the MannWhitney U test for ordinal scaled variables or the 2 test for nominally scaled variables. A value of P < 0.05 was considered statistically significant for all tests.
In subsequent multivariable binary logistic regression analysis, all socio-demographic and clinical parameters presenting a significance level of <0.150 (15%) in univariable analyses were entered into the respective model. Odds ratios are reported as point estimates with 95% CIs and P-values. Missing values were not imputed.
The LuLa cohort is approved by the Heinrich-HeineUniversity Dü sseldorf institutional review board (study numbers 2260 and 3708) and is registered in the German World Health Organization primary registry 'German Clinical Trials Register' (ID: DRKS00011052). This study did not require additional approval.
Results
The questionnaire was completed by 579 patients (94.0% female), with a mean (S.D.) age of 52.3 (13.4) years and disease duration of 16.8 (9.1) years. Further demographics and patient characteristics are presented in Table 1 .
Out of all the respondents, 82.9% reported owning a vaccine record card, 19.3% of whom stated that they did not use it. Their vaccination status was primarily checked by their GP (57.3%) and only occasionally by an internal specialist (7.9%), rheumatologist (7.6%) or others (8.5%). A quarter (24.9%) of the patients reported that their vaccination status was not checked by any of their attending physicians. Their clinical characteristics were not significantly different from participants whose vaccination status was checked, but 45.1% had rejected a vaccination before. The implementation of vaccinations was likewise mostly performed by the GP (72.4%) and less frequently by an internal specialist (8.1%), rheumatologist (5.9%) or others (5.2%). Ninety-three (16.1%) participants stated that at least one of their attending physicians had generally advised against the use of vaccinations. In most cases, this was recommended by their GP (6.6%) or rheumatologist (5.4%) and only rarely by an internal specialist (1.9%) or others (2.6%). Selected characteristics of the patients who had been advised against the use of vaccinations are outlined in Table 2 . Higher education was associated with a more frequent rejection of vaccinations, whereas the educational level of the patient showed no influence on the refusal behaviour by the treating physician or on the possession of a vaccination certificate.
There was no evidence for differences between the presented items or between single immunosuppressive agents (AZA, MTX, LEF, ciclosporin, MMF, CYC, rituximab, belimumab; not presented in the table) of the two patient groups in univariable analysis.
About one-third (37.5%) of the patients stated that they had rejected vaccinations before. Ninety-eight participants reported more than one reason for rejecting vaccinations, and four persons omitted their answer. The two main reasons expressed were the fear of developing a lupus flare (21.8%) or developing adverse events after vaccination (13.5%) (Fig. 1) .
Only accrued damage was significantly different between the two groups in univariable analysis, with more damage being reported by the participants who never rejected a vaccination [mean (S.D.) BILD score 2.2 (2.0) vs 1.9 (2.1); P = 0.009]. There was no evidence for differences in other demographic or clinical characteristics between the two groups.
Regarding the health locus of control and beliefs about medicines in the participants who rejected vaccinations, we observed a significantly lower HLC doc (control of doctor) and BMQ-benefit but higher BMQ-sensitivity and BMQ-overuse score compared with patients who had not rejected a vaccination before (P < 0.05 in univariable analysis). Other subscales remained non-significant. In multivariable logistic regression (including all items with P < 0.150; BILD, HLC doc , HLC chance , BMQ-overuse, BMQ-harm, BMQ-benefit, BMQ-sensitivity, BMQ-necessity and BMQ-concern) only HLC doc In Table 3 , coverage for selected vaccinations is listed. The frequencies are based on the number of persons eligible for the respective vaccination according to the recommendations of the German Society for Rheumatology respectively German Standing Committee on Vaccination.
The comparison of clinical and demographic differences between vaccinated and non-vaccinated participants depicts a higher age in individuals vaccinated with influenza or pneumococcal vaccine. There were no significant disparities in the level of education between the two groups. Other significant differences are presented in Table 4 . The items marked with a double asterisk or an asterisk show significant (**P < 0.05) or non-significant (*P < 0.15) differences, respectively, in univariable analysis that were included in the particular multivariable model. Multivariable analysis (Table 5) did not show significant covariates for the tetanus or meningococcal vaccination. An older age was associated with receiving influenza and a pneumococcal vaccination. Furthermore, less fatigue and treatment with CSs >7.5 mg increase the probability for receiving influenza vaccination.
As influenza and pneumococcal vaccinations are also recommended by the Standing Committee on Vaccination as standard vaccinations for people aged 560 years, we delimitated an additional analysis to participants <60 years of age but with immunosuppression as an indication to vaccinate. Multivariable analysis did not show significant covariates either for influenza or for pneumococcal vaccination.
Discussion
We observed a poor coverage for all studied vaccinations in our cohort. The highest rate was observed for tetanus, which has the lowest eligibility criteria for implementation. In the current national recommendations for vaccinations, it is recommended to anybody independent of age or co- morbidity. Our rates are at best on par compared with other reported vaccination rates for lupus patients, which are only scarcely published, or patients with other chronic conditions. The Lupus Outcome Study from the USA reported significantly higher vaccination rates for influenza (59%) and pneumococcal disease (60%) for eligible patients in 2005 [22] , as did a French population study among patients with RA and SpA [23] . In a large nationwide telephone sample survey in Germany in 2012, the vaccination coverage for tetanus in unselected persons and for influenza in persons with chronic disease was reported at 75.6 and 42.9%, respectively [7] , with a superior tetanus and comparable influenza coverage. In a French online survey addressing mixed immunocompromised patients, self-reported vaccine uptake against influenza was 59% and against pneumococcal disease 49% [24] . As vaccinations are one of the few effective preventive measures to avoid infections in potentially immunocompromised patients, the low reported coverage in our cohort is alarming. A recent paper from Germany published even worse vaccination rates (tetanus 37.7%, influenza past year 25.0%, pneumococcal disease 17.7%, meningococcal disease 0%) in 68 SLE patients from a university centre in 2011 [25] . Particularly regional specificities might explain these differences. Another reason could be the LuLa study's later date of enquiry, although this would presuppose a change in vaccination awareness.
Several patient-and physician-related reasons for the insufficient vaccination coverage can be identified in our study. Initially, the undecidedness of the supervising health-care professionals (HCP) towards the responsibility for checking and implementing vaccinations is of major importance. In Germany, most rheumatological patients are managed by a GP and a rheumatologist (>65% of the participants in our study), and additional HCPs might be involved. Nonetheless, we observed a high proportion of participants who reported not having their vaccination status checked by any of their attending physicians. Nearly half of the participants who did not have their status checked had rejected a vaccination before, possibly impacting the physician's conscientiousness. Nevertheless, the fact remains that the status was not checked within the other half of our participants, and it cannot legitimate the strikingly low rate of German rheumatologists checking vaccination status. A study from 2009 depicted Irish rheumatologists' vaccination behaviour. Most of them neither recommended nor recorded vaccination history in their clinical notes even before initiating immunosuppressive therapy. The majority of them regarded the rheumatology clinic not to be an appropriate setting for improving vaccine compliance and considered the patient's GP responsible for this domain [11] .
In our study, motives for objecting to vaccinations by the attending physicians remain vague. Owing to the nature of the LuLa study, we do not have information about the treating physicians and can only assume reasons from the patient's characteristics. We observed only minor numerical differences (lower mental health, more disease activity and damage, less use of immunosuppressants) in patients who were advised not to receive a vaccination, but none of those factors was significant. Other reasons must be of importance. A transfer of the patient's reservations onto the doctor might be causative. In our cohort, approximately two-thirds of the participants who reported objections by their physicians had rejected a vaccination themselves. This was also observed by Ridda et al. [26] in 2007, where GPs reported patients' refusal as a main reason for not vaccinating in 88% of the cases. On the contrary, literature reports the importance of a recommendation from their treating physician for patients' attitude to vaccination [23] . Therefore, the physicians' attitudes to vaccinations are of major importance. Nichol and Zimmerman [27] showed that those practitioners who had received a vaccination themselves and who believed that vaccinations are cost saving and effective strongly recommend vaccinations to their highrisk patients.
Rheumatologists have to consider the responsibility for explaining the importance of vaccinations and their safety to patients and co-operating doctors. We observe that the majority of checks and the vaccinations themselves are performed by the GP, who will most probably not be familiar with vaccination recommendations of the rheumatology societies and might have reservations and insecurities considering vaccinations in autoimmune disease or immunocompromised patients. On the contrary, the implementation of vaccination routines in the rheumatologist's office might comprise financial hurdles (lower cost-effectiveness owing to a lower frequency, conditionally lower discount and reimbursement issues). Therefore, the rheumatologist needs to communicate individualized recommendations to the GP. Pennant et al. and Desai et al. proved that vaccination adherence and, consequently, coverage can be improved in high-risk patient populations by simple quality measures such as improving routine workflow with physicians' pointof-care reminders. By using these measures, rates for pneumococcal vaccination by rheumatologists increased by 13.7%/3 years and 37%/6 years time period, respectively, at a tertiary center and its ambulatory training sites [28, 29] .
Other important reasons for non-vaccination are patient related. Only few demographic or clinical characteristics were identified that affect the vaccination status (age, fatigue and prednisone dosage in influenza vaccination, and age in pneumococcal vaccination). Immunosuppression as an additional important criterion of eligibility for vaccination was reflected only by the higher prednisone dosage in influenza vaccination. The lack of this signal concerning meningococcal or pneumococcal vaccinations emphasizes the fact that vaccination recommendations are implemented insufficiently. The selection of eligible patients for vaccination should be based more on risk factors than on age.
More than one-third of the participants had rejected vaccinations. The reasons for rejecting vaccinations were manifold. In the majority of cases, triggering of a lupus flare or vaccine damage was feared. Only very few patients doubted the protective effect of vaccines or feared a weakening of the immune system. In a large sample survey of the German population including 4483 persons conducted by the Federal Centre for Health Education in 2012 [30] and in a sample of French patients with inflammatory rheumatic diseases (RA and SpA) [23] , the fear of associated side-effects and doubt about the protective effect were observed more frequently than in our cohort. Therefore, in comparison with other cohorts, the fear of developing a disease flare provides a much more significant reservation in SLE. The risk of developing flares and the risk of developing SLE are often discussed in the literature. A recent meta-analysis depicted no impact of a pneumococcal or influenza vaccination on disease activity (measured by the SLEDAI) in 594 SLE patients [31] . Additionally, an international casecontrol study in France and Canada conducted between April 2008 and June 2012 showed no association between exposure to vaccinations and risk of developing SLE in 105 patients [32] .
Regarding the data derived from the health locus of control and beliefs about medicines questionnaires, we observed that a higher patient's belief that the doctor controls one's health and that medication is beneficial reduces the rejection of vaccinations. On the contrary, a higher probability of non-vaccination was detected in patients with a reported high sensitivity against medications.
These results depict that even common fears and trust can have an impact on vaccine hesitancy, which stresses the importance of individualized educative measures addressing the target group.
The data of our study are mainly representative for lupus patients in Germany. However, the patient-related barriers identified in our study are also likely to be important in other countries, cultures and health-care systems and might provide approaches to improve the ubiquitous unsatisfactory vaccination rates.
